CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
N-Acetyl Cysteine +1 moredrug
Likely dose
N-Acetyl Cysteine 1200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01063348
NCT01063348Phase 2Completed

A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Pathologic Skin Picking

University of Chicago·interventional·Posted Feb 5, 2010·Updated Feb 23, 2023

In Brief

A Phase 2 clinical trial evaluating N-Acetyl Cysteine and Placebo for Pathologic Skin Picking and 3 related conditions. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The goal of the proposed study is to evaluate the comparative efficacy of N-acetyl cysteine to placebo in pathologic skin picking. Thirty subjects with pathologic skin picking will receive 12 weeks of double-blind treatment with N-acetyl cysteine or matching placebo. The hypothesis to be tested is that N-acetyl cysteine will be more effective than placebo in patients with pathologic skin picking. The proposed study will provide needed data on the treatment of an often disabling disorder that currently lacks a clearly effective treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 5, 2010
Enrollment StartSep 1, 2012
Primary CompletionJul 1, 2015
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 16.4 years ago

Interventions

N-Acetyl Cysteinedrug

Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)

Placebodrug

Matching placebo capsules taken in same amount of pills as the active medication.